RESOLIAN BIOANALYTICS

Live / Registered — Registered (as of 04 Jun 2024)

What this means for you

Registered since 04 Jun 2024. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
97796233
Registration number
7410178
Mark type
Stylized text
Filed
15 Feb 2023
Published for opposition
09 Jan 2024
Registered
04 Jun 2024
Attorney of record
Christopher D. Olszyk, Jr.

Goods and services

  • Class 042 — Scientific and technological services: Laboratory testing services in clinical research and clinical trials of innovator and generic medicines in the pharmaceutical and biotechnology fields; Research and development in the fields of bioanalysis, immunoassay development, bioanalytical assay validation and testing, biomarker studies, drug metabolism, and pharmacokinetic testing; Pharmaceutical research and development services; Chemical, bioanalytical, biological and biotechnology research services; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines; Pharmaceutical drug development services; Scientific testing in the fields of oncology, neurology, gastroenterology, immunology, endocrinology, gene therapy, infectious disease, rare and orphan diseases, cardiovascular disease, metabolic disease, central nervous system, ophthalmology, and respiratory diseases, for medical and pharmaceutical research purposes; Drug and chemical materials analysis services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of pharmaceutical, biopharmaceutical, biotechnology and medical device development; Scientific analytical laboratory services; Good Manufacturing Practices (GMP) laboratory and stability testing and analytical services in the fields of pharmaceutical drug, pharmaceutical excipient, and consumer healthcare chemical development; Chemistry, Manufacturing, and Controls (CMC) laboratory and stability testing and analytical services in the fields of pharmaceutical drug, pharmaceutical excipient, and consumer healthcare chemical development; Analytical services, namely, providing Good Laboratory Practices (GLP) testing and quality assurance services to assess clinical performance in the field of therapeutic drug evaluation and development

Owner

Prosecution history

  • 04 Jun 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
  • 04 Jun 2024 — REGISTERED-PRINCIPAL REGISTER
  • 30 Apr 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
  • 30 Apr 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
  • 19 Apr 2024 — STATEMENT OF USE PROCESSING COMPLETE
  • 01 Apr 2024 — USE AMENDMENT FILED
  • 19 Apr 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
  • 01 Apr 2024 — TEAS STATEMENT OF USE RECEIVED
  • 05 Mar 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
  • 09 Jan 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 09 Jan 2024 — PUBLISHED FOR OPPOSITION
  • 20 Dec 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 02 Dec 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 29 Nov 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 28 Nov 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE

View this trademark record on Marksy